Allergan (NYSE:AGN) said the FDA approved 2 new styles of its Natrelle 410 silicone-filled breast implants, the Natrelle X and L.
“The Natrelle 410 X and L styles provide surgeons additional options to customize their patients’ fit by matching the implant’s height and width with the patient’s body type while providing optimal projection, based on the desired aesthetic outcome. The new Natrelle 410 X styles provide extra full projection, while the new L styles feature low height and low projection,” according to a press release.
The implants are approved for use in women undergoing breast augmentation, reconstruction or revision surgery.
The Natrelle 410 1st won FDA approval in February 2013, but the federal watchdog agency stipulated that Allergan run a post-approval study to keep an eye on its long-term safety and effectiveness.
Allergan has been fighting off a hostile, $54 billion takeover bid by Valeant Pharmaceuticals (NYSE:VRX, TSE:VRX). A rival bid of $60 billion by Actavis (ACT) is also reportedly in the works.